Economic Benefits and Diagnostic Quality of Diffusion-Weighted Magnetic Resonance Imaging for Primary Lung Cancer

Usuda, Katsuo; Funazaki, Aika; Maeda, Ryo; Sekimura, Atsushi; Motono, Nozomu; Matoba, Munetaka; Uramoto, Hidetaka

doi:10.5761/atcs.ra.17-00097

Cited by 16 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a non-invasive functional imaging technique, DWI can reflect changes in cell density and activity after treatment of tumors at the molecular level, far earlier than the conventional morphological changes, and evaluate the efficacy of treatment at the early stage [18]. The value of DWI in the early evaluation of the therapeutic effect of NSCLC has been studied intensively, which has been recognized by medical profession [19,20]. However, there is no study on the effect of DWI in early detection of drug resistance in lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Diffusion-Weighted Magnetic Resonance Imaging for Early Detection of Chemotherapy Resistance in Non-Small Cell Lung Cancer

Liu

Dong

et al. 2019

Med Sci Monit

View full text Add to dashboard Cite

BackgroundThe aim of this study was to examine the role of magnetic resonance imaging-diffusion weighted imaging (MRI-DWI) in the early detection of chemotherapy resistance in non-small cell lung cancer (NSCLC) patients.Material/MethodsMRI-DWI and computed tomography (CT) were carried out in 75 patients with newly diagnostic NSCLC before and after first, second, fourth, and sixth cycles of chemotherapy. Resistance to chemotherapy was assessed based on the change in the largest tumor diameter after chemotherapy. Diffusion of water molecule in each lesion was quantitatively measured by apparent diffusion coefficient (ADC). The diagnostic results of DWI after first and second cycle of chemotherapy were analyzed by the area under receiver operating characteristics curve (ROC).ResultsAmong the patients, 43 patients were chemo-resistance while 32 patients were chemo-sensitive. The ADC changing rate between second and first cycle of chemotherapy was significantly higher in chemo-sensitive patients compared with chemo-resistance patients (t=3.236, P=0.002). The ROC showed cutoff values of the ADC changing rate after first and second cycles of chemotherapy for resistance/sensitive discrimination were 23.6% and 5.56%, respectively. DWI after first and second cycles of therapy showed sensitivities of 55.8% and 55.8%, specificities of 65.6% and 87.5%, and area under ROC of 0.568 and 0.733, respectively.ConclusionsADC changing rate between first and second cycles of chemotherapy could sensitively distinguish chemo-sensitive and chemo-resistant tumors at earlier stages, which may direct treatment adjustment and improve the prognosis of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Diffusion-Weighted Magnetic Resonance Imaging for Early Detection of Chemotherapy Resistance in Non-Small Cell Lung Cancer

Liu

Dong

et al. 2019

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…The high cost of PET/CT compared with MRI is not limited to the United States alone. According to Usuda et al, a PET/CT is 81–84% more expensive compared with an MRI in Japan . For an administered activity of 370 MBq of 18 FDG, the effective dose from PET/CT was estimated to be 14.2 mSv in males and 17.2 mSv in females .…”

Section: Discussionmentioning

confidence: 99%

“…According to Usuda et al, a PET/CT is 81-84% more expensive compared with an MRI in Japan. 39 For an administered activity of 370 MBq of 18 FDG, the effective dose from PET/CT was estimated to be 14.2 mSv in males and 17.2 mSv in females. 40 In contrast, no radiation is associated with MRI.…”

Section: Discussionmentioning

confidence: 99%

Can MRI contribute to pulmonary nodule analysis?

Koo

Takahashi

et al. 2018

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Background There is no accurate method distinguishing different types of pulmonary nodules. Purpose To investigate whether multiparametric 3T MRI biomarkers can distinguish malignant from benign pulmonary nodules, differentiate different types of neoplasms, and compare MRI‐derived measurements with values from commonly used noninvasive imaging modalities. Study Type Prospective. Subjects Sixty‐eight adults with pulmonary nodules undergoing resection. Sequences Respiratory triggered diffusion‐weighted imaging (DWI), periodically rotated overlapping parallel lines with enhanced reconstruction (PROPELLER) fat saturated T2‐weighted imaging, T1‐weighted 3D volumetric interpolated breath‐hold examination (VIBE) using CAIPIRINHA (controlled aliasing in parallel imaging results in a higher acceleration). Assessment/Statistics Apparent diffusion coefficient (ADC), T1, T2, T1 and T2 normalized to muscle (T1/M and T2/M), and dynamic contrast enhancement (DCE) values were compared with histology to determine whether they could distinguish malignant from benign nodules and discern primary from secondary malignancies using logistic regression. Predictability of primary neoplasm types was assessed using two‐sample t‐tests. MRI values were compared with positron emission tomography / computed tomography (PET/CT) to examine if they correlated with standardized uptake value (SUV) or CT Hounsfield unit (HU). Intra‐ and interreader agreements were assessed using intraclass correlations. Results Forty‐nine of 74 nodules were malignant. There was a significant association between ADC and malignancy (odds ratio 4.47, P < 0.05). ADC ≥1.3 μm2/ms predicted malignancy. ADC, T1, and T2 together predicted malignancy (P = 0.003). No MRI parameter distinguished primary from metastatic neoplasms. T2 predicted PET positivity (P = 0.016). T2 and T1/M correlated with SUV (P < 0.05). Of 18 PET‐negative malignant nodules, 12 (67%) had an ADC ≥1.3 μm2/ms. With the exception of T2, all noncontrast MRI parameters distinguished adenocarcinomas from carcinoid tumors (P < 0.05). T1, T2, T1/M, and T2/M correlated with HU and therefore can predict nodule density. Combined with ADC, washout enhancement, arrival time (AT), peak enhancement intensity (PEI), Ktrans, Kep, Ve collectively were predictive of malignancy (P = 0.012). Combined washin, washout, time to peak (TTP), AT, and PEI values predicted malignancy (P = 0.043). There was good observer agreement for most noncontrast MRI biomarkers. Data Conclusion MRI can contribute to pulmonary nodule analysis. Multiparametric MRI might be better than individual MRI biomarkers in pulmonary nodule risk stratification. Level of Evidence: 1 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018.

show abstract

“…[25] , [97] , [98] , [99] , [100] , [101] , [102] , [103] , [104] , [105] , [106] , [107] , [108] , [109] , [110] , [111] , [112] , [113] , [114] , [115] , [143] , [144] , [145] , [146] , [147] , [148] , [149] , [150] , [151] , [152] , [153] , [154] , [155] , [156] , [157] , [158] , [159] , [160] , [161] , [162] , [163] , [164] , [165] , [166] , [167] , [168] , [169] , [170] , [171] , [172] …”

Section: Uncited Referencesunclassified

Magnetic particle targeting for diagnosis and therapy of lung cancers

Saadat

Manshadi

Mohammadi

et al. 2020

Journal of Controlled Release

View full text Add to dashboard Cite

Over the past decade, the growing interest in targeted lung cancer therapy has guided researchers toward the cutting edge of controlled drug delivery, particularly magnetic particle targeting. Targeting of tissues by magnetic particles has tackled several limitations of traditional drug delivery methods for both cancer detection (e.g., using magnetic resonance imaging) and therapy. Delivery of magnetic particles offers the key advantage of high efficiency in the local deposition of drugs in the target tissue with the least harmful effect on other healthy tissues. This review first overviews clinical aspects of lung morphology and pathogenesis as well as clinical features of lung cancer. It is followed by reviewing the advances in using magnetic particles for diagnosis and therapy of lung cancers: (i) a combination of magnetic particle targeting with MRI imaging for diagnosis and screening of lung cancers, (ii) magnetic drug targeting (MDT) through either intravenous injection and pulmonary delivery for lung cancer therapy, and (iii) computational simulations that models new and effective approaches for magnetic particle drug delivery to the lung, all supporting improved lung cancer treatment. The review further discusses future opportunities to improve the clinical performance of MDT for diagnosis and treatment of lung cancer and highlights clinical therapy application of the MDT as a new horizon to cure with minimal side effects a wide variety of lung diseases and possibly other acute respiratory syndromes (COVID-19, MERS, and SARS).

show abstract

Economic Benefits and Diagnostic Quality of Diffusion-Weighted Magnetic Resonance Imaging for Primary Lung Cancer

Cited by 16 publications

References 35 publications

Diffusion-Weighted Magnetic Resonance Imaging for Early Detection of Chemotherapy Resistance in Non-Small Cell Lung Cancer

Diffusion-Weighted Magnetic Resonance Imaging for Early Detection of Chemotherapy Resistance in Non-Small Cell Lung Cancer

Can MRI contribute to pulmonary nodule analysis?

Magnetic particle targeting for diagnosis and therapy of lung cancers

Contact Info

Product

Resources

About